menu
    • menu
    [{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"First Affiliated Hospital of Xinjiang Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"TNP-2092","moa":"||Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TenNor Therapeutics \/ First Affiliated Hospital of Xinjiang Medical University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ First Affiliated Hospital of Xinjiang Medical University"},{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"||DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NTC \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"National University of Malaysia \/ Santen Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"National University of Malaysia \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"UConn Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Inapplicable"},{"orgOrder":0,"company":"National Liver Institute, Egypt","sponsor":"Future Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"National Liver Institute, Egypt","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Liver Institute, Egypt \/ Future Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"National Liver Institute, Egypt \/ Future Pharmaceutical Industries"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"Searle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ Searle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Aga Khan University \/ Searle Pharmaceuticals"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"University of Karachi","sponsor":"Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Karachi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Karachi \/ Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi","highestDevelopmentStatusID":"6","companyTruncated":"University of Karachi \/ Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||Topoisomerase IV | DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Levofloxacin

    Menu

    Levofloxacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 19, 2017

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TenNor Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed

                            TenNor Therapeutics

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNP-2092,Vancomycin HCl,Rifampicin,Levofloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : First Affiliated Hospital of Xinjiang Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1/2 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 Administ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 21, 2025

                            Lead Product(s) : TNP-2092,Vancomycin HCl,Rifampicin,Levofloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : First Affiliated Hospital of Xinjiang Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP

                            Details : Levaquin-Generic (levofloxacin) is a fluoroquinolone antibiotic used to treat infections caused by bacteria. It is indicated for the treatment of pneumonia, acute bacterial sinusitis.

                            Product Name : Levaquin-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 27, 2024

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aga Khan University

                            Country arrow
                            EPSC
                            Not Confirmed

                            Aga Khan University

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Levofloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Searle Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2023

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Levofloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Searle Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PolyActiva

                            Australia arrow
                            EPSC
                            Not Confirmed

                            PolyActiva

                            Australia arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 01, 2022

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Karachi

                            Country arrow
                            EPSC
                            Not Confirmed

                            University of Karachi

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Levomerc 500 mg Tablets

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 21, 2022

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co | Center for bioequivalence studies and clinical reseach, ICCBS, University of Karachi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Liver Institute, Egypt

                            Country arrow
                            EPSC
                            Not Confirmed

                            National Liver Institute, Egypt

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Nitazoxanide,Doxycycline,Lansoprazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Future Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : Levofloxacin,Nitazoxanide,Doxycycline,Lansoprazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Future Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            UConn Health

                            Country arrow
                            EPSC
                            Not Confirmed

                            UConn Health

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftriaxone,Amoxicillin Trihydrate,Clavulanic Acid,Cefepime,Vancomycin Hydrochloride,Levofloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Early Antibiotics After Aspiration in ICU Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 15, 2021

                            Lead Product(s) : Ceftriaxone,Amoxicillin Trihydrate,Clavulanic Acid,Cefepime,Vancomycin Hydrochloride,Levofloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PolyActiva

                            Australia arrow
                            EPSC
                            Not Confirmed

                            PolyActiva

                            Australia arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Levofloxacin Ocular Implant for Ocular Surgery

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Levofloxacin,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Santen Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Santen Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levofloxacin,Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            7-day Levofloxacin/Dexamethasone Eye Drops as Effective as Standard Treatment After Cataract Surgery

                            Details : The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye drops were as effective as 14-day tobramycin/dexamethasone eye drops to treat ocular inflammation and prevent infection in post-cataract surgery patients.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 13, 2020

                            Lead Product(s) : Levofloxacin,Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth